AOP Orphan`s Sugammadex Approved In Europe
AOP Orphan`s Sugammadex Amomed (Sugammadex) Receives Approval in Europe
Majority of patients treated with Ropeginterferon alfa-2b achieved deep molecular responses (mutant JAK2 allele burden below 10%): allele burden decreased from median 37.3% at baseline to 7.3%, while it increased from 38.1% to 42.6% in the control group (p<0.0001).